STOCK TITAN

Evolus Announces Inducement Grants for New Chief Financial Officer

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Very Positive)
Tags
Rhea-AI Summary

Evolus, Inc. (NASDAQ: EOLS) announced stock options and restricted stock units (RSUs) granted to Sandra Beaver, the new Chief Financial Officer, on September 5, 2022. These include 169,158 stock options with an exercise price of $9.06 and 36,443 RSUs. The options vest over four years, with 25% vesting annually. This grant complies with Nasdaq Listing Rule 5635(c)(4), emphasizing the company's commitment to attracting and retaining talent. Evolus focuses on innovative beauty products and the aesthetic neurotoxin market through its flagship product, Jeuveau®.

Positive
  • Grant of 169,158 stock options and 36,443 RSUs to new CFO Sandra Beaver, demonstrating commitment to talent retention.
  • Stock options have a 10-year term and vest over 4 years, aligning management incentives with shareholder interests.
Negative
  • None.

NEWPORT BEACH, Calif.--(BUSINESS WIRE)-- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today announced that the Compensation Committee of the Board of Directors approved the grant of stock options to purchase an aggregate of 169,158 shares of Evolus common stock and 36,443 restricted stock units (RSUs) to Sandra Beaver, the company’s new Chief Financial Officer. The stock options and RSUs were granted as of September 5, 2022 and were approved in accordance with Nasdaq Listing Rule 5635(c)(4) as a material inducement to the employee’s acceptance of employment with the company.

The stock options have an exercise price of $9.06 per share, the closing price of Evolus’ common stock on September 2, 2022, the last trading day prior to Ms. Beaver’s start date. The stock options have a 10-year term and vest over 4 years, with 25% of the number of shares subject to the option vesting on each annual anniversary of Ms. Beaver’s first day of employment. The RSUs vest 25% on each annual anniversary of Ms. Beaver’s start date. Both the stock options and the RSUs are subject to acceleration in certain events including certain terminations or upon certain terminations in connection with a change in control of Evolus. The stock options and RSUs were granted outside of Evolus’ 2017 Omnibus Incentive Plan.

About Evolus, Inc.

Evolus (Nasdaq: EOLS) is a performance beauty company evolving the aesthetic neurotoxin market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global, multi-product aesthetics company based on our flagship product, Jeuveau® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure™ technology. Visit us at www.evolus.com, and follow us on LinkedIn, Twitter, Instagram or Facebook.

Jeuveau® and Nuceiva® are registered trademarks of Evolus, Inc.
Hi-Pure is a trademark of Daewoong Pharmaceutical Co, Ltd.

Investor/Media Contact

David K. Erickson, Evolus, Inc.

Vice President, Investor Relations

949-966-1798

david.erickson@evolus.com

Source: Evolus

FAQ

What was announced by Evolus, Inc. regarding stock options on September 5, 2022?

Evolus announced the grant of 169,158 stock options and 36,443 restricted stock units (RSUs) to new CFO Sandra Beaver.

What is the exercise price of the stock options granted to Sandra Beaver?

The stock options have an exercise price of $9.06 per share, which is the closing price on September 2, 2022.

How does the vesting schedule work for the stock options and RSUs granted to Sandra Beaver?

The stock options vest 25% annually over four years, while the RSUs also vest 25% on each annual anniversary of her start date.

What is the significance of the stock options grant for Evolus, Inc.?

The grant is intended as a material inducement for Sandra Beaver's acceptance of employment and aligns her interests with those of the shareholders.

Evolus, Inc.

NASDAQ:EOLS

EOLS Rankings

EOLS Latest News

EOLS Stock Data

689.57M
50.17M
12.31%
80.25%
8.35%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States of America
NEWPORT BEACH